European Journal of Clinical Pharmacology

, Volume 53, Issue 5, pp 299–302

European network for the case–population surveillance of rare diseases (Euronet). A prospective feasibility study

  • D. Capellà
  • J.-R. Laporte
  • X. Vidal
  • B.-E. Wiholm
  • B. Bégaud
  • M. J. S. Langman
  • M. Rawlins
PHARMACOEPIDEMIOLOGY AND PRESCRIPTION

DOI: 10.1007/s002280050382

Cite this article as:
Capellà, D., Laporte, JR., Vidal, X. et al. E J Clin Pharmacol (1998) 53: 299. doi:10.1007/s002280050382

Abstract

Objective: Euronet, a case-population surveillance scheme, aims to estimate the risk of certain rare conditions which are commonly iatrogenic, by comparing drug use amongst non-selective cases with overall drug use in the general population.

Methods: The method is based on three provisos: (1) all incident cases (irrespective of suspected aetiology) should be ascertained and studied; (2) a full drug history should be obtained from cases by direct interview; and (3) drug-use data for the products of interest should be available for this population from which cases are chosen. The feasibility of this problem-oriented approach for the identification of new signals of adverse drug reactions and for risk estimation will be tested in relation to agranulocytosis, Stevens-Johnson syndrome and toxic epidermal necrolysis in four defined areas in Europe, totalling 19 × 106 inhabitants, with these latest two outcomes being studied in only three regions. The design, methods and main limitations of this case–population surveillance approach are described.

Key words Surveillance of rare diseaseEuropean net work

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • D. Capellà
    • 1
  • J.-R. Laporte
    • 1
  • X. Vidal
    • 1
  • B.-E. Wiholm
    • 2
  • B. Bégaud
    • 3
  • M. J. S. Langman
    • 4
  • M. Rawlins
    • 5
  1. 1.Institut Català de Farmacologia, Universitat Autònoma de Barcelona, CSU Vall d'Hebron, Pg Vall d'Hebron, 119-129, E-08035 Barcelona, Spain Tel. +34 3 428 30 29/428 31 76; Fax +34 3 489 41 09; e-mail: jrl@icf.uab.esES
  2. 2.Medical Products Agency, Uppsala, Department of Clinical Pharmacology, Karolinska Institute, SwedenSE
  3. 3.Centre de Pharmacovigilance Bordeaux-Aquitaine, Hôpital Pellegrin, Bordeaux, FranceFR
  4. 4.Department of Medicine, University of Birmingham, UKGB
  5. 5.Wolfson Unit of Clinical Pharmacology, University of Newcastle, Newcastle upon Tyne, UKGB